Phase II Study of CDK 4/6 Inhibitor, LEE011 (Ribociclib), in Combination With Adjuvant Endocrine Therapy at Varying Duration for ER-positive Breast Cancer (LEADER)

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 03 Apr 2024

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Ribociclib (Primary) ; Aromatase inhibitors
Indications Advanced breast cancer; Early breast cancer; HER2 negative breast cancer
Focus Therapeutic Use
Acronyms LEADER

06 Dec 2023 According to a Natera media release, data from this study are being presented at the 2023 San Antonio Breast Cancer Symposium (SABCS).
07 Dec 2022 According to a Natera media release, new clinical data on its personalized and tumor-informed molecular residual disease (MRD) test, Signatera, and its hereditary cancer test, Empower, will be presented at the 2022 San Antonio Breast Cancer Symposium (SABCS) in San Antonio, Texas.
25 Oct 2021 Planned End Date changed from 1 Oct 2024 to 1 Oct 2026.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com